New perspectives of the treatment of urogenital atrophy in women: intravaginal DHEA therapy

Krzysztof Gałczyński; Ewa Poleszak; Regina Kasperek; Katarzyna Romanek-Piva; Beata Kulik-Rechberger; Tomasz Rechberger

doi:10.5114/pm.2013.35064

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2013
vol. 12

Send email

Copy url:

abstract:

Review paper

New perspectives of the treatment of urogenital atrophy in women: intravaginal DHEA therapy

Krzysztof Gałczyński

,

Ewa Poleszak

,

Regina Kasperek

,

Katarzyna Romanek-Piva

,

Beata Kulik-Rechberger

,

Tomasz Rechberger

Przegląd Menopauzalny 2013; 2: 111–114

DOI: https://doi.org/10.5114/pm.2013.35064

Online publish date: 2013/05/13

View full text Get citation

PlumX metrics:

According to novel theory menopausal symptoms are not only connected with estrogen deficiency due to diminished ovarian estrogen secretion, but are also associated with the gradual, progressive decline in the level of dehydroepiandrosterone (DHEA) secreted by the adrenal glands. Over 50% of postmenopausal women report symptoms associated with urogenital atrophy, ie: irritation, recurrent infections, dryness, dyspareunia. Systemic hormonal therapy with estrogens or in combination with progestins is an effective treatment of these symptoms, however, it is associated with some adverse effects. In addition, it is worthwhile to think about local therapy in case of women who have only symptoms associated with urogenital atrophy. Promising are results of the studies of DHEA intravaginal therapy, in which it was assumed that physiological doses of DHEA contribute to an increase in androgens and estrogens synthesized locally in tissues by intracrine mechanisms with low systemic effects. Previous studies have shown that intravaginal DHEA application reduce the symptoms of vaginal atrophy, regress low-grade cervical dysplasia and increase libido.

keywords:

New perspectives of the treatment of urogenital atrophy in women: intravaginal DHEA therapy

Krzysztof Gałczyński , Ewa Poleszak , Regina Kasperek , Katarzyna Romanek-Piva , Beata Kulik-Rechberger , Tomasz Rechberger

dehydroepiandrosterone, urogenital atrophy, menopause

Krzysztof Gałczyński

,

Ewa Poleszak

,

Regina Kasperek

,

Katarzyna Romanek-Piva

,

Beata Kulik-Rechberger

,

Tomasz Rechberger